Listed

National Vision Holdings, Inc.: Form 10-Q for the period ended Mar 28, 2020

Filed with the SEC on May 7, 2020 and accepted by EDGAR at May 7, 2020, 06:24 ET.

Share

Management's discussion and analysis

As filed, 71,509 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

The following contains management’s discussion and analysis of our financial condition and results of operations and should be read together with the unaudited condensed consolidated financial statements and the related notes thereto included elsewhere in this Form 10-Q (this “Form 10-Q”) and the audited consolidated financial statements and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on February 26, 2020 (the “Annual Report”). This discussion contains forward-looking statements that reflect our plans, estimates and beliefs and involve numerous risks and uncertainties, including, but not limited to, those described in the “Risk Factors” section of the Annual Report and in the “Risk Factors” section of this Form 10-Q, as such risk factors may be updated from time to time in our periodic filings with the SEC. Actual results may differ materially from those contained in any forward-looking statements. You should carefully read “Special Note Regarding Forward-Looking Statements” in this Form 10-Q.

Overview

We are one of the largest and fastest growing optical retailers in the United States and a leader in the attractive value segment of the U.S. optical retail industry. We believe that vision is central to quality of life and that people deserve to see their best to live their best, no matter what their budget. Our mission is to make quality eye care and eyewear affordable and accessible to all Americans. We achieve this by providing eye exams, eyeglasses and contact lenses to value seeking and lower income consumers. We deliver exceptional value and convenience to our customers, with an opening price point that strives to be among the lowest in the industry, enabled by our low-cost operating platform. We reach our customers through a diverse portfolio of 1,173 retail stores across five brands and 19 consumer websites as of March 28, 2020.

Recent Developments - COVID-19

The unprecedented and rapid spread of the COVID-19 pandemic and the related federal, state and local governmental and healthcare authority guidelines have caused business disruption globally and in the U.S. As of the date of filing this Quarterly Report on Form 10-Q, there are many uncertainties regarding the COVID-19 pandemic, including the anticipated duration of the pandemic and the extent of national and global social and economic disruption it may cause. To date, the COVID-19 pandemic and government and healthcare authority actions to curb the spread of the virus have had far-reaching impacts, directly and indirectly, on our operations, including the temporary closure of our stores to the public beginning in March 2020, and on consumer behavior, comparable store sales, our employees and optometrists, and the overall market. The scope and nature of these impacts continue to evolve on a daily basis. The COVID-19 pandemic has resulted in, and may continue to result in, state, city or local quarantines, labor stoppages and shortages, changes in consumer purchasing patterns, mandatory or voluntary shut-downs of retail locations, severe market volatility, liquidity disruptions, and overall economic instability, which, in many cases, have had, and we expect will continue to have, material adverse impacts on our business, financial condition and results of operations. This situation is rapidly changing, and additional impacts may arise that we are not aware of currently. In response to the evolving and uncertain situation, we have taken aggressive and prudent actions to minimize the risk to our Company, employees, customers and the communities in which we operate, along with reducing expenses and deferring discretionary capital expenditures. Some of our actions taken include:

  • On March 17, 2020, as a precautionary measure to preserve financial flexibility during the COVID-19 pandemic, we borrowed the remaining $146.3 million in available funds under our revolving credit facility. The total borrowings of $300.0 million represents the maximum borrowings permitted thereunder, at an interest rate of LIBOR plus a 1.50% per annum;
  • On March 19, 2020, we temporarily closed all of our stores to the public across the United States;
  • We implemented expense reduction initiatives including a pause in new store openings, reduced near term marketing spend, and reduced compensation and work hours across the organization;
  • On April 7, 2020, we temporarily furloughed a significant portion of our employees;
  • Where possible, we have attempted to ship eyeglasses and contact lenses from our labs and distribution centers directly to customers who had placed orders in our stores and otherwise would have picked them up in our stores;
  • We identified additional expense reductions that we intend to implement throughout the remainder of fiscal 2020 as necessary, including working with a base of vendors and landlords to extend payment terms and modify existing contracts;
  • We have suspended all non-essential travel for our employees;
  • On April 23, 2020, we announced plans to re-open stores selectively over the coming weeks with a goal for all stores within our family of retail brands to be open to the public by early June; and
  • Effective May 5, 2020, the Company and the lenders under its credit facility entered into an amendment of the facility. This amendment is intended to prevent the effects of the COVID-19 pandemic, including the temporary closure of our stores, from creating uncertainty relative to our ability to comply with certain financial covenants and allow the Company to focus on prudent management of the business over the quarters ahead. The amendment suspends certain financial maintenance covenants contained in the facility until testing at the end of the second fiscal quarter of 2021. As part of the amendment, the Company among other things agreed to modify the rate of interest paid under the facility and to limit its ability to engage in certain transactions during the covenant suspension period, including the ability to declare or pay dividends, incur additional debt and make investments and dispositions.

In addition to the foregoing actions by the Company, members of management and our Board of Directors have taken the following actions with respect to their compensation, which we expect will remain in place either for the time period indicated or at least until the Company’s stores reopen or conditions improve:

  • Reade Fahs, our Chief Executive Officer, has elected to reduce his base salary to $1 for the remainder of 2020;
  • Each of the other members of the Company’s senior management team have elected to take significant reductions in base salary; and
  • The members of our Board of Directors unanimously elected to reduce the remainder of their respective annual cash retainer fees for 2020 to $1 for their service on our Board.

The COVID-19 pandemic and responsive measures taken by the Company have had, and we expect will continue to have, material adverse impacts on our current business, financial condition and results of operations, and may create additional risks for our Company. While we anticipate that these measures are temporary, their specific duration has a high degree of uncertainty and we may elect or need to take additional measures as the situation continues to evolve, including with respect to our employees, store leases and relationships with third-party vendors. We will continue to assess the evolving COVID-19 pandemic and its impact on our customers, employees, optometrists, supply chain and operations and will adjust our responsive measures accordingly. However, the extent to which the COVID-19 pandemic and our precautionary measures in response thereto may impact our business, financial condition and results of operations will depend on how the pandemic and its impacts continue to develop, which are highly uncertain. We are continuing to evaluate additional operational and financial measures that we may elect to take as we continue to respond to the impact of COVID-19 on our business, including obtaining additional debt and/or equity capital to provide further liquidity in the coming months. There can be no assurance whether or when any such measures will be adopted.

The disclosures contained in this Form 10-Q are made only as of the date hereof, and we undertake no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as required by law. For further information, please see “Risk Factors” and “Forward-Looking Statements.”

Brand and Segment Information

Our operations consist of two reportable segments:

  • Owned & Host - As of March 28, 2020, our owned brands consisted of 747 America’s Best Contacts and Eyeglasses (“America’s Best”) retail stores and 117 Eyeglass World retail stores. In America’s Best stores, vision care services are provided by optometrists employed by us or by independent professional corporations or similar entities. America’s Best stores are primarily located in high-traffic strip centers next to value-focused retailers. Eyeglass World locations primarily feature vision care services provided by independent optometrists and optometrists employed by independent professional corporations or similar entities and on-site optical laboratories that enable stores to quickly fulfill many customer orders and make repairs on site. Eyeglass World stores are primarily located in freestanding or in-line locations near high-foot-traffic shopping centers. Our host brands consisted of 54 Vista Optical locations on military bases and 29 Vista Optical locations within Fred Meyer stores as of March 28, 2020. We have strong, long-standing relationships with our host partners and have maintained each partnership for over 20 years. These brands provide eye exams primarily by independent optometrists. All brands utilize our centralized laboratories. This segment also includes sales from our America’s Best, Eyeglass World, and Military omni-channel websites.
  • Legacy - We manage the operations of, and supply inventory and laboratory processing services to, 226 Vision Centers in Walmart retail locations as of March 28, 2020. This strategic relationship with Walmart is in its 30th year. Pursuant to a January 2020 amendment to our management & services agreement with Walmart, we will be adding five additional Vision Centers in Walmart stores in fiscal year 2020. In addition, the amendment also extended the current term of the management & services agreement by six months, to February 23, 2021, and such term will automatically renew for an additional three-year term unless, no later than July 23, 2020, one party provides the other party written notice of non-renewal. Under the management & services agreement, our responsibilities include ordering and maintaining merchandise inventory; arranging the provision of optometry services; providing managers and staff at each location; training personnel; providing sales receipts to customers; maintaining necessary insurance; obtaining and holding required licenses, permits and accreditations; owning and maintaining store furniture, fixtures and equipment; and developing annual operating budgets and reporting. We earn management fees as a result of providing such services and therefore we record revenue related to sales of products and product protection plans to our legacy partner’s customers on a net basis. Our management & services agreement also allows our legacy partner to collect penalties if the Vision Centers do not generate a requisite amount of revenues. No such penalties have been assessed under our current arrangement, which began in 2012. We also sell to our legacy partner merchandise that is stocked in retail locations we manage pursuant to a separate supplier agreement, and provide centralized laboratory services for the finished eyeglasses for our legacy partner’s customers in stores that we manage. We lease space from Walmart within or adjacent to each of the locations we manage and use this space for vision care services provided by independent optometrists or optometrists employed by us or by independent professional corporations or similar entities. During the three months ended March 28, 2020, sales associated with our legacy partner arrangement represented 7.8% of consolidated net revenue. This exposes us to concentration of customer risk.

Our consolidated results also include the following activity recorded in our Corporate/Other category:

  • Our e-commerce platform of 15 dedicated websites managed by AC Lens. Our e-commerce business consists of six proprietary branded websites, including aclens.com, discountglasses.com and discountcontactlenses.com, and nine third-party websites with established retailers, such as Walmart, Sam’s Club and Giant Eagle as well as mid-sized vision insurance providers. AC Lens handles site management, customer relationship management and order fulfillment and also sells a wide variety of contact lenses, eyeglasses and eye care accessories.
  • AC Lens also distributes contact lenses wholesale to Walmart and Sam’s Club. We incur costs at a higher percentage of sales than other product categories. AC Lens sales associated with Walmart and Sam’s Club contact lenses distribution arrangements represented 8.6% of consolidated net revenue.
  • Managed care business conducted by FirstSight, our wholly-owned subsidiary that is licensed as a single-service health plan under California law, which arranges for the provision of optometric services at the offices next to certain Walmart stores throughout California, and also issues individual vision care benefit plans in connection with our America’s Best operations in California.
  • Unallocated corporate overhead expenses, which are a component of selling, general and administrative expenses and are comprised of various home office expenses such as payroll, occupancy costs, and consulting and professional fees. Corporate overhead expenses also include field services for our five retail brands.

Reportable segment information is presented on the same basis as our consolidated financial statements, except reportable segment sales which are presented on a cash basis including point of sales for managed care payors and excluding the effects of unearned and deferred revenue, consistent with what our chief operating decision maker (“CODM”) regularly reviews. Reconciliations of segment results to consolidated results include financial information necessary to adjust reportable segment revenues to a consolidated basis in accordance with U.S. GAAP, specifically the change in unearned and deferred revenues during the period. There are no revenue transactions between reportable segments, and there are no other items in the reconciliations other than the effects of unearned and deferred revenue. See Note 10. “Segment Reporting” in our consolidated financial statements included in Part I. Item 1. of this Form 10-Q.

Deferred revenue represents the timing difference of when we collect the cash from the customer and when services related to product protection plans and eye care club memberships are performed. Increases or decreases in deferred revenue during the reporting period represent cash collections in excess of or below the recognition of previous deferrals. Unearned revenue represents the timing difference of when we collect cash from the customer and delivery/customer acceptance, and includes sales of prescription eyewear during approximately the last seven to 10 days of the reporting period.

Trends and Other Factors Affecting Our Business

COVID-19 Impact

The COVID-19 pandemic has had far-reaching impacts, directly and indirectly, on our operations. We are monitoring the impacts COVID-19 has had, and continues to have, on our outsourced third party optical laboratories in China and Mexico, including potential disruptions of product deliveries. We have currently been able to meet customer demand with operations at our laboratories. We source merchandise from suppliers located in China and a significant amount of domestically-purchased merchandise is manufactured in China. We are partnering with our suppliers and third party laboratories to mitigate any potential significant delays in delivery of merchandise upon store operations resuming. Our ecommerce business remains open to serve our customers during this unprecedented period of temporary store closures.

We have seen, and expect to continue to see, material reductions in sales across brands and regions as a result of COVID-19. In addition, these reductions in revenue have not been offset by proportional decreases in expense, as we continue to incur store occupancy costs, and certain other costs such as compensation and administrative expenses, resulting in a negative effect on profitability. In addition, we could experience other material impacts as a result of COVID-19, including, but not limited to, charges from additional asset impairment, deferred tax valuation allowances and changes in the effectiveness of our hedging instruments. The current circumstances are dynamic and the impacts of COVID-19 on our business operations, including the duration and impact on overall customer demand, are highly uncertain, although COVID-19 has had and will continue to have a material adverse impact on our business, results of operations, financial condition and cash flows in fiscal 2020 to date.

It is possible that our preparations for the events listed above are not adequate to mitigate their impact, and that these events could further adversely affect our business and results of operations. For a discussion of recent actions taken by the Company, refer to “Recent Developments - COVID-19” above in this Form 10-Q. For discussion of significant risks that have the potential to cause our actual results to differ materially from our expectations, refer to “Item 1A. Risk Factors,” included in our Annual Report on Form 10-K for the year ended December 28, 2019 and in this Form 10-Q.

Long-term trends and factors

We remain committed to our long-term vision and continue to position ourselves to make progress against our key initiatives while balancing the near-term challenges and unprecedented uncertainty presented by the COVID-19 pandemic. As a result of the COVID-19 pandemic, we implemented expense reduction initiatives including a pause in new store openings, reduced near term marketing spend, and reduced compensation and work hours across the organization and are working with a base of vendors and landlords to extend payment terms and modify existing contracts. We experienced negative comparable store sales growth in the first quarter of 2020 as a result of the closure of our stores in response to the COVID-19 pandemic, and anticipate that comparable store sales growth figures for the rest of the fiscal year 2020 as well as fiscal year 2021 will be impacted by the pandemic. We believe that the following trends and factors will continue to be exacerbated by the immediate and ongoing threat of the COVID-19 pandemic:

  • New store openings;
  • Comparable store sales growth;
  • Managed care and insurance;
  • Vision care professional recruitment and coverage;
  • Overall economic trends;
  • Consumer preferences and demand;
  • Infrastructure and investment;
  • Pricing strategy;
  • Inflation;
  • Interim results and seasonality;
  • Competition; and
  • Consolidation in the industry

How We Assess the Performance of Our Business

While we have historically attempted to exercise prudence in our use of cash, the COVID-19 pandemic has required us to closely monitor various items related to cash flow including, but not limited to, cash receipts, cash disbursements, payment terms and alternative sources of funding. We will continue to be focused on these items in addition to the other key measures we use to determine how our consolidated business and operating segments are performing, including: net revenue, costs applicable to revenue, and selling, general, and administrative expenses. In addition, we also review store growth, Adjusted Comparable Store Sales Growth, Adjusted Operating Income, Adjusted Operating Margin, Adjusted EBITDA, Adjusted EBITDA Margin and Adjusted Diluted EPS.

Net Revenue

We report as net revenue amounts generated in transactions with retail customers who are the end users of our products, services, and plans. Net product sales include sales of prescription and non-prescription eyewear, contact lenses, and related accessories as well as eye exam services associated with our America’s Best brand’s signature offer of two pairs of eyeglasses and a free eye exam for one low price (“two-pair offer”) to retail customers and sales of inventory in which our customer is another retail entity. Net sales of services and plans include sales of eye exams, eye care club memberships, product protection plans (i.e., warranties), and single service eye care plans in California. Net sales of services and plans also include fees we earn for managing certain Vision Centers located in Walmart stores and for laboratory services provided to Walmart.

Costs Applicable to Revenue

Costs applicable to revenue include both costs of net product sales and costs of net sales of services and plans. Costs of net product sales include (i) costs to procure non-prescription eyewear, contact lenses, and accessories, which we purchase and sell in finished form, (ii) costs to manufacture finished prescription eyeglasses, including direct materials, labor, and overhead, and (iii) remake costs, warehousing and distribution expenses, and internal transfer costs. Costs of services and plans include costs associated with product protection plan programs, eye care club memberships, single service eye care plans in California, eye care practitioner and eye exam technician payroll, taxes and benefits and optometric and other service costs. Customer tastes and preferences, product mix, changes in technology, significant increases or slowdowns in production, and other factors impact costs applicable to revenue. The components of our costs applicable to revenue may not be comparable to other retailers.

Selling, General and Administrative

Selling, general and administrative expenses, or SG&A, include store associate (including optician) payroll, taxes and benefits, occupancy, advertising and promotion, field services, corporate support and other costs associated with the provision of vision care services. Non-capital expenditures associated with opening new stores, including rent, store maintenance, marketing expenses, travel and relocation costs, and training costs, are recorded in SG&A as incurred. SG&A generally fluctuates consistently with revenue due to the variable store, field office and corporate support costs; however, some fixed costs slightly improve as a percentage of net revenue as our net revenues grow over time.

New Store Openings

The total number of new stores per year and the timing of store openings has, and will continue to have, an impact on our results. In an effort to conserve cash during the COVID-19 pandemic, we have paused new store openings and will monitor when to resume new store openings based on health, safety and economic conditions.

Adjusted Comparable Store Sales Growth

We measure Adjusted Comparable Store Sales Growth as the increase or decrease in sales recorded by the comparable store base in any reporting period, compared to sales recorded by the comparable store base in the prior reporting period, which we calculate as follows: (i) sales are recorded on a cash basis (i.e., when the order is placed and paid for or submitted to a managed care payor, compared to when the order is delivered), utilizing cash basis point of sale information from stores; (ii) stores are added to the calculation during the 13th full fiscal month following the store’s opening; (iii) closed stores are removed from the calculation for time periods that are not comparable; (iv) sales from partial months of operation are excluded when stores do not open or close on the first day of the month; and (v) when applicable, we adjust for the effect of the 53rd week. Quarterly, year-to-date and annual adjusted comparable store sales are aggregated using only sales from all whole months of operation included in both the current reporting period and the prior reporting period. When a partial month is excluded from the calculation, the corresponding month in the subsequent period is also excluded from the calculation. There may be variations in the way in which some of our competitors and other retailers calculate comparable store sales. As a result, our adjusted comparable store sales may not be comparable to similar data made available by other retailers. We did not adjust our calculation of Adjusted Comparable Store Sales Growth for the temporary closure of our stores to the public as a result of the COVID-19 pandemic.

Adjusted Comparable Store Sales Growth is a non-GAAP financial measure, which we believe is useful because it provides timely and accurate information relating to the two core metrics of retail sales: number of transactions and value of transactions. We use Adjusted Comparable Store Sales Growth as the basis for key operating decisions, such as allocation of advertising to particular markets and implementation of special marketing programs. Accordingly, we believe that Adjusted Comparable Store Sales Growth provides timely and accurate information relating to the operational health and overall performance of each brand. We also believe that, for the same reasons, investors find our calculation of Adjusted Comparable Stores Sales Growth to be meaningful.

Adjusted EBITDA, Adjusted EBITDA Margin Adjusted Operating Income, Adjusted Operating Margin, and Adjusted Diluted EPS (collectively, the “Company Non-GAAP Measures”)

The Company Non-GAAP Measures are key measures used by management to assess our financial performance. The Company Non-GAAP Measures are also frequently used by analysts, investors and other interested parties. We use The Company Non-GAAP Measures to supplement U.S. GAAP measures of performance to evaluate the effectiveness of our business strategies, to make budgeting decisions, to establish discretionary annual incentive compensation and to compare our performance against that of other peer companies using similar measures. See “Non-GAAP Financial Measures” for definitions of the Company Non-GAAP Measures and for additional information.

Results of Operations

The following table summarizes key components of our results of operations for the periods indicated, both in dollars and as a percentage of our net revenue.

In thousands, except store data

Revenue: Three Months Ended March 28, 2020 March 30, 2019
Net product sales $392,841 $383,160
Net sales of services and plans 76,863 78,055
Total net revenue 469,704 461,215
Costs applicable to revenue (exclusive of depreciation and amortization):
Products 156,370 154,004
Services and plans 62,184 57,965
Total costs applicable to revenue 218,554 211,969
Operating expenses:
Selling, general and administrative expenses 193,741 193,876
Depreciation and amortization 24,810 20,415
Asset impairment 11,355 2,082
Litigation settlement 4,395 —
Other expense (income), net (66) 473
Total operating expenses 234,235 216,846
Income from operations 16,915 32,400
Interest expense, net 7,455 9,061
Earnings before income taxes 9,460 23,339
Income tax provision (benefit) (282) 5,910
Net income $9,742 $17,429
Operating data:
Number of stores open at end of period 1,173 1,105
New stores opened 23 26
Adjusted Operating Income $38,063 $42,656
Diluted EPS $0.12 $0.21
Adjusted Diluted EPS $0.28 $0.31
Adjusted EBITDA $61,022 $61,220
Percentage of net revenue Three Months Ended March 28, 2020 March 30, 2019
Total costs applicable to revenue 46.5% 46.0%
Selling, general and administrative 41.2% 42.0%
Total operating expenses 49.9% 47.0%
Income from operations 3.6% 7.0%
Net income 2.1% 3.8%
Adjusted Operating Income 8.1% 9.2%
Adjusted EBITDA 13.0% 13.3%

31

Three Months Ended March 28, 2020 compared to Three Months Ended March 30, 2019

Net revenue

The following presents, by segment and by brand, comparable store sales growth, stores open at the end of the period and net revenue for the three months ended March 28, 2020 compared to the three months ended March 30, 2019.

In thousands, except percentage and store data

Owned & Host segment Comparable store sales growth(1) Three Months Ended March 28, 2020 Three Months Ended March 30, 2019 Stores open at end of period March 28, 2020 March 30, 2019 Net revenue(2) Three Months Ended March 28, 2020 Three Months Ended March 30, 2019
America’s Best (9.3)% 8.2% 747 679 $294,170 62.6% $305,096 66.2%
Eyeglass World (12.1)% 6.5% 117 116 44,486 9.5% 50,214 10.9%
Military (12.1)% (4.4)% 54 54 5,642 1.2% 6,421 1.4%
Fred Meyer (16.0)% (9.7)% 29 29 2,929 0.6% 3,489 0.8%
Owned & Host segment total 947 878 $347,227 73.9% $365,220 79.3%
Legacy segment (14.0)% 1.8% 226 227 36,457 7.8% 44,578 9.7%
Corporate/Other — — — — 66,571 14.2% 63,881 13.7%
Reconciliations — — — — 19,449 4.1% (12,464) (2.7)%
Total (2.9)% 6.2% 1,173 1,105 $469,704 100.0% $461,215 100.0%
Adjusted Comparable Store Sales Growth(3) (10.3)% 6.7%

(1) We calculate total comparable store sales based on consolidated net revenue excluding the impact of (i) Corporate/Other segment net revenue, (ii) sales from stores opened less than 13 months, (iii) stores closed in the periods presented, (iv) sales from partial months of operation when stores do not open or close on the first day of the month and (v) if applicable, the impact of a 53rd week in a fiscal year. Brand-level comparable store sales growth is calculated based on cash basis revenues consistent with what the CODM reviews, and consistent with reportable segment revenues presented in Note 10. “Segment Reporting” in our unaudited condensed consolidated financial statements included in Part I. Item 1. of this Form 10-Q, with the exception of the Legacy segment, which is adjusted as noted in clause (ii) of footnote (3) below.

(2) Percentages reflect line item as a percentage of net revenue, adjusted for rounding.

(3) There are two differences between total comparable store sales growth based on consolidated net revenue and Adjusted Comparable Store Sales Growth: (i) Adjusted Comparable Store Sales Growth includes the effect of deferred and unearned revenue as if such revenues were earned at the point of sale, resulting in a decrease of 7.5% and an increase of 0.8% from total comparable store sales growth based on consolidated net revenue for the three months ended March 28, 2020 and March 30, 2019, respectively, and (ii) Adjusted Comparable Store Sales Growth includes retail sales to the legacy partner’s customers (rather than the revenues recognized consistent with the management & services agreement with the legacy partner), resulting in an increase of 0.1% and a decrease of 0.3% from total comparable store sales growth based on consolidated net revenue for the three months ended March 28, 2020 and March 30, 2019, respectively.

Total net revenue of $469.7 million for the three months ended March 28, 2020 increased $8.5 million, or 1.8%, from $461.2 million for the three months ended March 30, 2019. This increase was driven primarily by recognition of unearned revenue and increased sales in new stores opened after the first quarter of 2019, which were partially offset by reduced comparable store sales growth from COVID-19 related temporary store closures beginning in March 2020.

In the three months ended March 28, 2020, we opened 23 new America’s Best stores and closed one America’s Best store. Overall, store count grew 6.2% from March 30, 2019 to March 28, 2020 (68 and one net new America’s Best and Eyeglass World stores were added, respectively, and one legacy store closed during the same period). Comparable store sales growth and Adjusted Comparable Store Sales Growth were (2.9)% and (10.3)%, respectively, for the three months ended March 28, 2020.

Comparable store sales growth and Adjusted Comparable Store Sales Growth were negative due to the closure of our retail stores from March 19, 2020 through the end of the first quarter of 2020 as a result of the COVID-19 pandemic. Comparable store sales growth and Adjusted Comparable Store Sales Growth for the two months ended February 29, 2020 were 5.6% and 5.7%, respectively. Comparable store sales growth and Adjusted Comparable Store Sales Growth for the one month ended March 28, 2020 were (18.8)% and (41.5)%, respectively. Adjusted Comparable Stores Sales Growth includes the effect of deferred and unearned revenue as if such revenues were earned at the point of sale, resulting in a decrease of 0.2% and 22.5% for the two months ended February 29, 2020 and the one month ended March 28, 2020, respectively. Adjusted Comparable Store Sales Growth includes retail sales to the legacy partner’s customers (rather than the revenues recognized consistent with the management & services agreement with the legacy partner), resulting in an increase of 0.3% and a decrease of 0.2% for the two months ended February 29, 2020 and the one month ended March 28, 2020, respectively.

Net product sales comprised 83.6% and 83.1% of total net revenue for the three months ended March 28, 2020 and March 30, 2019, respectively. Net product sales increased $9.7 million, or 2.5%, in the three months ended March 28, 2020 compared to the three months ended March 30, 2019, driven primarily by contact lens revenue growth. Net sales of services and plans decreased $1.2 million, or 1.5%, primarily due to temporary store closures beginning in March 2020.

Owned & Host segment net revenue. Net revenue declined $18.0 million, or 4.9%, due to the temporary closure of the Company’s stores to the public in response to the COVID-19 pandemic.

Legacy segment net revenue. Net revenue decreased $8.1 million, or 18.2%, due to the temporary closure of the Company’s stores to the public in response to the COVID-19 pandemic.

Corporate/Other segment net revenue. Net revenue increased $2.7 million, or 4.2%, driven by unit growth in our online retail business.

Net revenue reconciliations. The impact of reconciliations increased net revenue by $31.9 million in the three months ended March 28, 2020 compared to the three months ended March 30, 2019. Reconciliations include a decrease in unearned revenue of $19.9 million for the three months ended March 28, 2020 compared to an increase in unearned revenue of $7.8 million for the three months ended March 30, 2019, and increases in deferred revenue of $0.5 million and $4.7 million, for the three months ended March 28, 2020 and March 30, 2019, respectively. While we usually experience increases in unearned revenue for sales in the last seven to 10 days of each quarter, the temporary closure of our stores to the public from March 19, 2020 through the end of the first quarter of 2020 caused virtually all of this increase to not be realized. We anticipate that consolidated revenue in future quarters will be affected by the recognition of unearned revenue and deferred revenue once our stores are re-opened and operating at full capacity.

Costs applicable to revenue

Costs applicable to revenue of $218.6 million for the three months ended March 28, 2020 increased $6.6 million, or 3.1%, from $212.0 million for the three months ended March 30, 2019. As a percentage of net revenue, costs applicable to revenue increased from 46.0% for the three months ended March 30, 2019 to 46.5% for the three months ended March 28, 2020. This increase as a percentage of net revenue was primarily driven by optometrist costs incurred during temporary store closures to the public as well as contact lens revenue growth, partially offset by higher eyeglass margin.

Costs of products as a percentage of net product sales decreased from 40.2% for the three months ended March 30, 2019 to 39.8% for the three months ended March 28, 2020, driven primarily by higher eyeglass margin partially offset by contact lens revenue growth.

Owned & Host segment costs of products. Costs of products as a percentage of net product sales increased from 28.7% for the three months ended March 30, 2019 to 29.1% for the three months ended March 28, 2020 driven by contact lens revenue growth offset by higher eyeglass margin.

Legacy segment costs of products. Costs of products as a percentage of net product sales decreased from 46.9% for the three months ended March 30, 2019 to 46.7% for the three months ended March 28, 2020. The decrease was primarily driven by a lower mix of non-managed care customer transactions. Decreases in managed care mix increase costs of products as a percentage of net product sales and have a corresponding positive impact on costs of services as a percentage of net sales of services and plans in our Legacy segment. Legacy segment managed care net product revenue is recorded in net product sales while revenue associated with servicing non-managed care customers is recorded in net sales of services and plans. Eyeglass and contact lens product costs for both managed care and non-managed care net revenue are recorded in costs of products.

Costs of services and plans as a percentage of net sales of services and plans increased from 74.3% for the three months ended March 30, 2019 to 80.9% for the three months ended March 28, 2020. The increase was primarily driven by optometrist costs incurred during temporary store closures.

Owned & Host segment costs of services and plans. Costs of services and plans as a percentage of net sales of services and plans increased from 75.6% for the three months ended March 30, 2019 to 85.1% for the three months ended March 28, 2020. The increase was driven by optometrist and technician costs incurred during temporary store closures.

Legacy segment costs of services and plans. Costs of services and plans as a percentage of net sales of services and plans increased from 43.6% for the three months ended March 30, 2019 to 54.7% for the three months ended March 28, 2020. The increase was primarily driven by optometrist costs incurred during temporary store closures.

Selling, general and administrative

SG&A of $193.7 million for the three months ended March 28, 2020 decreased $0.1 million, or 0.1%, from the three months ended March 30, 2019. As a percentage of net revenue, SG&A decreased from 42.0% for the three months ended March 30, 2019 to 41.2% for the three months ended March 28, 2020. The decrease in SG&A as a percentage of net revenue was primarily due to recognition of unearned revenue from the fourth quarter of 2019 that was not offset by unearned revenue at the end of the first quarter of 2020, as well as lower performance-based incentive compensation expense, partially offset by store payroll expense incurred during temporary store closures.

Owned & Host SG&A. SG&A as a percentage of net revenue increased from 36.5% for the three months ended March 30, 2019 to 38.8% for the three months ended March 28, 2020, driven primarily due to store payroll and occupancy costs incurred during temporary store closures in March 2020.

Legacy segment SG&A. SG&A as a percentage of net revenue increased from 31.9% for the three months ended March 30, 2019 to 37.4% for the three months ended March 28, 2020 primarily driven by decreased revenue as a result of temporary store closures in March 2020.

Depreciation and amortization

Depreciation and amortization expense of $24.8 million for the three months ended March 28, 2020 increased $4.4 million, or 21.5%, from $20.4 million for the three months ended March 30, 2019 primarily driven by investments in new lab equipment. Our property and equipment balance, net, decreased $17.0 million, or 4.6%, during the three months ended March 28, 2020, reflective of $16.2 million in purchases of property and equipment, $1.2 million in new finance leases, less $23.0 million in depreciation expense, and $11.4 million in impairment expense and other adjustments.

Asset Impairment

We recognized $11.4 million for impairment primarily of tangible long-lived assets and ROU assets associated with our retail stores during the three months ended March 28, 2020 compared to $2.1 million recognized during the three months ended March 30, 2019. The impairment charges were primarily related to our Owned & Host segment and were driven by lower than projected customer sales volume in certain stores, and were determined using entity-specific assumptions related to our anticipated use of store assets. We considered multiple factors including, but not limited to: forecasted scenarios related to store performance and likelihood that these scenarios would be ultimately realized; the historical performance of the stores before the temporary store closures in response to the COVID-19 pandemic; and the remaining useful lives of the assets. Asset impairment expenses were recognized in Corporate/Other.

Interest expense, net

Interest expense, net, of $7.5 million for the three months ended March 28, 2020 decreased $1.6 million, or 17.7%, from $9.1 million for the three months ended March 30, 2019, primarily as a result of our term loan refinancing in 2019.

Income tax provision

Our income tax expense for the three months ended March 28, 2020 reflected income tax expense at our statutory federal and state rate of 25.5%, offset by a discrete benefit of $2.7 million associated primarily with the exercise of stock options. During the three months ended March 30, 2019, our expected combined statutory federal and state rate was reduced by a $0.2 million income tax benefit resulting from stock option exercises.

Non-GAAP Financial Measures

EBITDA, Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Operating Income, Adjusted Operating Margin and Adjusted Diluted EPS

We define EBITDA as net income, plus interest expense, income tax provision and depreciation and amortization. We define Adjusted EBITDA as net income, plus interest expense, income tax provision and depreciation and amortization, further adjusted to exclude stock compensation expense, loss on extinguishment of debt, asset impairment, litigation settlement, secondary offering expenses, management realignment expenses, long-term incentive plan expenses, and other expenses. We define Adjusted EBITDA Margin as Adjusted EBITDA as a percentage of net revenue. We define Adjusted Operating Income as net income, plus interest expense and income tax provision, further adjusted to exclude stock compensation expense, asset impairment, litigation settlement, secondary offering expenses, management realignment expenses, long-term incentive plan expenses, amortization of acquisition intangibles, and other expenses. We define Adjusted Operating Margin as Adjusted Operating Income as a percentage of net revenue. We define Adjusted Diluted EPS as diluted earnings per share, adjusted for the per share impact of stock compensation expense, loss on extinguishment of debt, asset impairment, litigation settlement, secondary offering expenses, management realignment expenses, long-term incentive plan expenses, other expenses, amortization of acquisition intangibles and deferred financing costs, and tax benefit of stock option exercises, less the tax effect of these adjustments.

In the first quarter of 2020, we introduced Adjusted Operating Income and Adjusted Operating Margin as measures of performance we will use in connection with Adjusted EBITDA, Adjusted EBITDA Margin and Adjusted Diluted EPS. Further, consistent with our presentation of Adjusted Operating Income, we no longer exclude new store pre-opening expenses and non-cash rent from our presentation of Adjusted EBITDA and Adjusted Diluted EPS. New store pre-opening expenses totaled $0.9 million for each of the three months ended March 28, 2020 and March 30, 2019; and non-cash rent totaled $0.6 million and $1.2 million for the three months ended March 28, 2020 and March 30, 2019, respectively. The presentation of Adjusted EBITDA and Adjusted Diluted EPS for the three months ended March 30, 2019 has been recast to reflect these changes. See our Form 8-K filed with the SEC on February 26, 2020, which is incorporated herein by reference, for more information.

EBITDA and the Company Non-GAAP Measures can vary substantially in size from one period to the next, and certain types of expenses are non-recurring in nature and consequently may not have been incurred in any of the periods presented below.

EBITDA and the Company Non-GAAP Measures have been presented as supplemental measures of financial performance that are not required by, or presented in accordance with U.S. GAAP, because we believe they assist investors and analysts in comparing our operating performance across reporting periods on a consistent basis by excluding items that we do not believe are indicative of our core operating performance. Management believes EBITDA and the Company Non-GAAP Measures are useful to investors in highlighting trends in our operating performance, while other measures can differ significantly depending on long-term strategic decisions regarding capital structure, the tax jurisdictions in which we operate and capital investments. We also use EBITDA and the Company non-GAAP Measures to supplement U.S. GAAP measures of performance in the evaluation of the effectiveness of our business strategies, to make budgeting decisions, to establish discretionary annual incentive compensation and to compare our performance against that of other peer companies using similar measures. Management supplements U.S. GAAP results with non-GAAP financial measures to provide a more complete understanding of the factors and trends affecting the business than U.S. GAAP results alone.

EBITDA and the Company non-GAAP Measures are not recognized terms under U.S. GAAP and should not be considered as an alternative to net income or income from operations as a measure of financial performance or cash flows provided by operating activities as a measure of liquidity, or any other performance measure derived in accordance with U.S. GAAP. Additionally, these measures are not intended to be a measure of free cash flow available for management’s discretionary use as they do not consider certain cash requirements such as interest payments, tax payments and debt service requirements. EBITDA and the Company non-GAAP Measures should not be construed to imply that our future results will be unaffected by unusual or non-recurring items. In evaluating EBITDA and the Company Non-GAAP Measures you should be aware that in the future we may incur expenses that are the same as or similar to some of the adjustments in this presentation. Our presentation of EBITDA and the Company Non-GAAP Measures should not be construed to imply that our future results will be unaffected by any such adjustments. Management compensates for these limitations by primarily relying on our U.S. GAAP results in addition to using EBITDA and the Company Non-GAAP Measures.

The presentations of these measures have limitations as analytical tools and should not be considered in isolation, or as a substitute for analysis of our results as reported under U.S. GAAP. Some of these limitations are:

  • they do not reflect costs or cash outlays for capital expenditures or contractual commitments;
  • they do not reflect changes in, or cash requirements for, our working capital needs;
  • EBITDA and Adjusted EBITDA do not reflect the interest expense, or the cash requirements necessary to service interest or principal payments, on our debt;
  • EBITDA and Adjusted EBITDA do not reflect period to period changes in taxes, income tax expense or the cash necessary to pay income taxes;
  • they do not reflect the impact of earnings or charges resulting from matters we consider not to be indicative of our ongoing operations;
  • although depreciation and amortization are non-cash charges, the assets being depreciated and amortized will often have to be replaced in the future, and EBITDA and Adjusted EBITDA do not reflect cash requirements for such replacements; and
  • other companies in our industry may calculate these measures differently than we do, limiting their usefulness as comparative measures.

Because of these limitations, EBITDA and the Company Non-GAAP Measures should not be considered as measures of discretionary cash available to invest in business growth or to reduce indebtedness.

The following table reconciles our Adjusted Operating Income and Adjusted Operating Margin to net income; and EBITDA, Adjusted EBITDA, Adjusted EBITDA Margin and Adjusted Diluted EPS for the periods presented:

In thousands

Three Months Ended March 28, 2020 March 30, 2019
Net income $9,742 2.1% $17,429 3.8%
Interest expense 7,455 1.6% 9,061 2.0%
Income tax provision (benefit) (282) (0.1)% 5,910 1.3%
Stock compensation expense (a) 2,093 0.4% 2,976 0.6%
Asset impairment (b) 11,355 2.4% 2,082 0.5%
Litigation settlement (c) 4,395 0.9% — —%
Management realignment expenses (d) — —% 2,155 0.5%
Other (e) 1,454 0.3% 1,192 0.3%
Amortization of acquisition intangibles (i) 1,851 0.4% 1,851 0.4%
Adjusted Operating Income / Adjusted Operating Margin $38,063 8.1% $42,656 9.2%
Note: Percentages reflect line item as a percentage of net revenue, adjusted for rounding. Some of the percentage totals in the table above do not foot due to rounding differences

36

In thousands

Three Months Ended March 28, 2020 March 30, 2019
Net income $9,742 2.1% $17,429 3.8%
Interest expense 7,455 1.6% 9,061 2.0%
Income tax provision (benefit) (282) (0.1)% 5,910 1.3%
Depreciation and amortization 24,810 5.3% 20,415 4.4%
EBITDA 41,725 8.9% 52,815 11.5%
Stock compensation expense (a) 2,093 0.4% 2,976 0.6%
Asset impairment (b) 11,355 2.4% 2,082 0.5%
Litigation settlement (c) 4,395 0.9% — —%
Management realignment expenses (d) — —% 2,155 0.5%
Other (e) 1,454 0.3% 1,192 0.3%
Adjusted EBITDA / Adjusted EBITDA Margin $61,022 13.0% $61,220 13.3%
Note: Percentages reflect line item as a percentage of net revenue, adjusted for rounding. Some of the percentage totals in the table above do not foot due to rounding differences

In thousands, except per share amounts

Three Months Ended March 28, 2020 March 30, 2019
Diluted EPS $0.12 $0.21
Stock compensation expense (a) 0.03 0.04
Asset impairment (b) 0.14 0.03
Litigation settlement (c) 0.05 —
Management realignment expenses (d) — 0.03
Other (e) 0.02 0.01
Amortization of acquisition intangibles and deferred financing costs (f) 0.03 0.03
Tax benefit of stock option exercises (g) (0.03) —
Tax effect of total adjustments (h) (0.07) (0.04)
Adjusted Diluted EPS $0.28 $0.31
Weighted average diluted shares outstanding 82,242 81,466
Note: Some of the totals in the table above do not foot due to rounding differences

(a) Non-cash charges related to stock-based compensation programs, which vary from period to period depending on the timing of awards and performance vesting conditions.

(b) Reflects write-off of property, equipment and lease related assets on closed or underperforming stores for the three months ended March 28, 2020 and March 30, 2019.

(c) Expenses associated with settlement of litigation. See Note 9. “Commitments and Contingencies” in our consolidated financial statements for further details.

(d) Expenses related to a non-recurring management realignment described in our Current Report on Form 8-K filed with the SEC on January 10, 2019.

(e) Other adjustments include amounts that management believes are not representative of our operating performance (amounts in brackets represent reductions in Adjusted Operating Income, Adjusted Diluted EPS and Adjusted EBITDA), including our share of losses on equity method investments of $0.6 million for the three months ended March 30, 2019; the amortization impact of adjustments related to the March 2014 acquisition of the Company by affiliates of KKR & Co. Inc. (the “KKR Acquisition”), (e.g., fair value of leasehold interests) of $0.1 million for each of the three months ended March 28, 2020 and March 30, 2019; costs of severance and relocation $0.3 million and $0.2 million for the three months ended March 28, 2020 and March 30, 2019, respectively; excess payroll taxes related to stock option exercises of $0.3 million for the three months ended March 28, 2020; $0.6 million of incremental costs directly related to adapting the Company’s operations during the COVID-19 pandemic for the three months ended March 28, 2020; and other expenses and adjustments totaling $0.2 million and $0.3 million for the three months ended March 28, 2020 and March 30, 2019, respectively.

(f) Amortization of the increase in carrying values of finite-lived intangible assets resulting from the application of purchase accounting to the KKR Acquisition of $1.9 million for each of the three months ended March 28, 2020 and March 30, 2019. Amortization of deferred financing costs is associated with deferred financing fees and amortization of debt discounts related to term loan and revolving credit facility borrowings totaling $0.2 million and $0.4 million for the three months ended March 28, 2020 and March 30, 2019, respectively.

(g) Tax benefit associated with accounting guidance, requiring excess tax benefits related to stock option exercises to be recorded in earnings as discrete items in the reporting period in which they occur.

(h) Represents the income tax effect of the total adjustments at our combined statutory federal and state income tax rates.

(i) Amortization of the increase in carrying values of finite-lived intangible assets resulting of purchase accounting to the KKR Acquisition.

Liquidity and Capital Resources

While we have historically relied on cash flows from operations as our primary source of liquidity, in the first quarter of 2020, as precautionary measure to preserve financial flexibility in light of the uncertainties surrounding the COVID-19 pandemic, we borrowed the remaining $146.3 million in available funds under our revolving credit facility (as defined below). Our primary cash needs are for inventory, payroll, store rent, capital expenditures associated with new stores and updating existing stores, as well as information technology and infrastructure, including our corporate office, distribution centers, and laboratories. We are prioritizing cash conservation and prudent use of cash, while positioning the Company to safely return to normal operations as soon as possible. The most significant components of our operating assets and liabilities are inventories, accounts receivable, prepaid expenses and other assets, accounts payable, deferred and unearned revenue and other payables and accrued expenses. We believe that cash expected to be generated from operations and the cash from the drawdown of our revolving credit facility in March 2020 will be sufficient to fund our working capital requirements, liquidity obligations, anticipated capital expenditures, and payments due under our existing credit facilities for at least the next 12 months. The Company is continuing to evaluate additional operational and financial measures that it may elect to take as it continues to respond to the impact of COVID-19 on its business, including obtaining additional debt and/or equity capital to provide further liquidity in the coming months. There can be no assurance whether or when any such measures will be adopted.

As of March 28, 2020, we had $263.2 million in cash and cash equivalents, and have fully drawn our $300.0 million revolving credit facility, which includes $5.7 million in outstanding letters of credit.

We purchased $13.1 million in capital items in the three months ended March 28, 2020. Approximately 80% of our capital spend is related to our expected growth (i.e., new stores, optometric equipment, additional capacity in our optical laboratories and distribution centers, and our IT infrastructure, including omni-channel platform related investments). We opened 23 new stores during the three months ended March 28, 2020, but have paused the opening of new stores in light of the COVID-19 pandemic. Our working capital requirements for inventory will increase as we continue to open additional stores. We primarily fund our working capital needs using cash provided by operations.

The following table summarizes cash flows provided by (used for) operating activities, investing activities and financing activities for the periods indicated:

In thousands

Cash flows provided by (used for): Three Months Ended March 28, 2020 March 30, 2019
Operating activities $86,060 $83,014
Investing activities (12,854) (25,806)
Financing activities 150,601 (1,354)
Net increase in cash, cash equivalents and restricted cash $223,807 $55,854

Net Cash Provided by Operating Activities

Cash flows provided by operating activities increased $3.0 million from $83.0 million during the three months ended March 30, 2019 to $86.1 million for the three months ended March 28, 2020. The increase in cash provided by operating activities consisted of a decrease in net income of $7.7 million and increase of non-cash expense items of $5.2 million including decreases in deferred income tax expense of $6.2 million, credit loss expense of $1.6 million and $0.9 million in stock based compensation expense offset by increases in non-cash expense items including depreciation and amortization of $4.4 million, and asset impairment charges of $9.3 million.

Decreases in net working capital and other assets and liabilities contributed $5.6 million in cash compared to the three months ended March 30, 2019. The decrease in net working capital consisted of increases in accounts payable during the three months ended March 28, 2020, which contributed $17.7 million in year-over-year cash, primarily due to timing of payments, and decreases in accounts receivable of $25.7 million, primarily caused by decreases in credit card receivables as a result of store closures near the end of the first quarter of 2020.

Offsetting these items were other liabilities of $25.0 million, of which $27.0 million decrease in year-over-year cash was due to the timing of unearned revenue as a result of store closures, which was partially offset by an increase of $7.3 million in year-over-year cash due to timing of rent related payments. Deferred revenue contributed to a $4.2 million decrease in year-over-year cash due to lower sales of club and purchase protection plans as a result of store closures. Increases in inventory used $7.3 million in year-over-year cash, due to timing of forward buys.

Net Cash Used for Investing Activities

Net cash used for investing activities decreased by $13.0 million, to $12.9 million, during the three months ended March 28, 2020 from $25.8 million during the three months ended March 30, 2019. The decrease was primarily due timing of new store capital investments.

Net Cash Provided By (Used For) Financing Activities

Net cash provided by (used for) financing activities increased $152.0 million, from $1.4 million use of cash during the three months ended March 30, 2019 to $150.6 million provision of cash during the three months ended March 28, 2020. The increase in cash provided by financing activities was primarily related to the additional borrowing of $146.3 million under the revolving credit facility in March 2020.

Term Loan and Revolving Credit Facility

As of March 28, 2020, we had $392.4 million of first lien term loan outstanding under our credit agreement. As of March 28, 2020, we also had a $300.0 million revolving credit facility with $294.3 million outstanding, including $5.7 million in outstanding letters of credit.

The interest rate payable on the first lien term loan is based on either LIBOR or an alternative borrowing rate plus an additional rate that varies between depending on NVI’s consolidated first lien leverage ratio. The first lien term loan will amortize in quarterly installments equal to 2.50% per annum in the first three years of the loan and 5.00% per annum thereafter.

In addition, under our credit agreement we must maintain certain covenants based on our financial results. Our credit agreement also contains covenants that, among other things, limit NVI’s ability to incur additional debt, create liens against assets, make acquisitions, pay dividends or distributions on its stock, merge or consolidate with another entity and transfer or sell assets. As of March 28, 2020, we were in compliance with all of our debt covenants under our credit agreement.

May 2020 Amendment to Credit Agreement

On May 5, 2020, we entered into an agreement (the “Amendment”) with the lenders under our credit facility in order to amend certain provisions of the credit agreement. As set forth in greater detail below, the principal purpose of the Amendment was to suspend certain financial maintenance covenants contained in the credit agreement until testing at the end of the second fiscal quarter of 2021. Capitalized terms used but not defined herein shall have the meanings assigned to such terms in the credit agreement and Amendment, as applicable.

Pursuant to the Amendment, the financial covenants relating to maintenance of a maximum Consolidated Total Debt to Consolidated EBITDA Ratio and a minimum Consolidated Interest Coverage Ratio are suspended until testing at the end of the second fiscal quarter of 2021. From and after such time, such covenants will be reinstated on a modified basis so that, subject to certain exceptions and limitations as described in the Amendment, (i) with respect to the second and third fiscal quarters of 2021, the Consolidated Total Debt to Consolidated EBITDA Ratio shall not exceed 4.50 to 1.00 and, with respect to the fourth fiscal quarter of fiscal 2021 and thereafter, the Consolidated Total Debt to Consolidated EBITDA Ratio shall not exceed 4.00 to 1.00, in each case with NVI being able to elect to annualize certain quarterly periods so that quarterly performance from fiscal 2020 is excluded and (ii) with respect to the second fiscal quarter of 2021 and thereafter, the Consolidated Interest Coverage Ratio shall not be less than 3.00 to 1.00. In lieu of such financial covenants, pursuant to the Amendment NVI will agree during the suspension period, (i) not to have Consolidated EBITDA for any six fiscal quarter period be less than $0, with the second fiscal quarter of 2020 permitted to be excluded in certain circumstances, and (ii) to have a minimum level of liquidity (defined as cash and cash equivalents plus the unused portion of the revolving credit facility) equal to the lesser of (x) $100,000,000 and (y) $40,000,000 plus the amount of any net proceeds from capital markets financings during such period in excess of $75,000,000.

In addition, the credit agreement was amended pursuant to the Amendment to, among other things, (i) limit the flexibility of NVI and Holdings with respect to certain transactions during the covenant suspension period, including the ability to declare or pay dividends, incur debt and make investments and dispositions, (ii) require prepayments of the term loans under certain circumstances during the covenant suspension period from the net proceeds from debt or equity capital markets transactions by the Company (with the amount of the term loans to be paid down equal to $75 million from the first $400 million of capital raised and 50% of any proceeds above such amount) and (iii) restrict NVI’s ability to borrow under the revolving credit facility if unrestricted cash and cash equivalents exceeds $50 million (and, in the event of any such excess, to require a mandatory prepayment of such amount). Also pursuant to the Amendment, the margins upon which interest is calculated for the term loans were amended to a range of 1.75% to 2.75% (for LIBOR Loans) and 1.75% to 1.00% (for ABR Loans), in each case based on NVI’s Consolidated First Lien Secured Debt to Consolidated EBITDA Ratio at such time, with such margins subject an increase of 50 basis points in the event that either (i) the Company has not raised at least $135 million in additional proceeds from certain capital markets transactions within 30 days of the date of the Amendment or (ii) Consolidated EBITDA for the most recently ended fiscal period is less than $0.

Future cash requirements and sources of cash

The Company’s capital allocation strategy, priorities and investments are reviewed by the Company’s Board of Directors considering both liquidity and severity of impacts to the business resulting from COVID-19.

Primary sources of cash

The Company’s primary source of cash to execute its growth strategy is its operating cash flows, used to fund operations throughout the fiscal year and to support future growth. The Company entered this period of COVID-19 uncertainty with a healthy liquidity position and is taking immediate, aggressive and prudent actions, including reevaluating all expenditures, to enhance the Company’s ability to meet the business’ short-term liquidity needs, in order to best position the business for its key stakeholders, including the Company’s associates, customers and shareholders.

Primary uses of cash

The Company’s current capital allocation strategy is to prioritize navigating the near-term challenges that COVID-19 presents and continuing to fund operating activities. In response to COVID-19, the Company is taking immediate, aggressive and prudent actions, including reevaluating all expenditures, to enhance the Company’s ability to meet the business’ short-term liquidity needs and has paused opening new stores. As a result, over the next twelve months, the Company expects its primary cash requirements to be towards funding operating activities, including the acquisition of inventory, and obligations related to compensation, leases and any lease modifications it may exercise, taxes and other operating activities.

The Company also evaluates opportunities for investments in line with our key initiatives that position the business for sustainable long-term growth. These improvements may include opening new stores, improving store experiences or investments in its omni-channel initiatives or other technology opportunities. In addition, the Company evaluates store closures, including options to terminate store leases early at certain underperforming locations. Historically, the Company has utilized free cash flow generated from operations to fund any discretionary capital expenditures, which have been prioritized towards new store openings, as well as digital and omni-channel investments, information technology, and other projects.

When appropriate, the Company may utilize excess liquidity, towards debt service requirements, including voluntary debt prepayments, or required interest and principal payments, if any, based on excess cash flows.

Off-balance Sheet Arrangements

We follow U.S. GAAP in making the determination as to whether or not to record an asset or liability related to our arrangements with third parties. Consistent with current accounting guidance, we do not record an asset or liability associated with long-term purchase, marketing and promotional commitments, or commitments to philanthropic endeavors. We have disclosed the amount of future commitments associated with these items in our fiscal year 2019 annual consolidated financial statements filed on the Form 10-K. We were not a party to any other off-balance sheet arrangements.

Contractual Obligations

As a result of our prepayment of debt principal in 2019 the Company does not owe principal payments on its term loan in 2020 and 2021. There were no other material changes outside the ordinary course of business in our contractual obligations and commercial commitments from those reported as of December 28, 2019 in the Annual Report.

Critical Accounting Policies and Estimates

Management has evaluated the accounting policies used in the preparation of the Company’s unaudited condensed consolidated financial statements and related notes and believes those policies to be reasonable and appropriate. Certain of these accounting policies require the application of significant judgment by management in selecting appropriate assumptions for calculating financial estimates. By their nature, these judgments are subject to an inherent degree of uncertainty. These judgments are based on historical experience, trends in the industry, information provided by customers and information available from other outside sources, as appropriate. The most significant areas involving management judgments and estimates may be found in the Annual Report dated December 28, 2019, in the “Critical Accounting Policies and Estimates” section of “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” There have been no material changes to our critical accounting policies as compared to the critical accounting policies described in the Annual Report, except for the adoption of Accounting Standards Update (“ASU”) No. 2016-13, Measurement of Credit Losses on Financial Instruments, and ASU No. 2018-15, Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract discussed in Note 1. “Description of Business and Basis of Presentation” of our unaudited condensed consolidated financial statements included in Part I. Item 1. of this Form 10-Q.

Adoption of New Accounting Pronouncements

The information set forth in Note 1. “Description of Business and Basis of Presentation” to our unaudited condensed consolidated financial statements under Part I. Item 1. under the heading “Adoption of New Accounting Pronouncements” of this Form 10-Q is incorporated herein by reference.

Market risk

As filed, 1,935 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

We have market risk exposure from changes in interest rates. When appropriate, we use derivative financial instruments to mitigate the risk from such exposure. A discussion of our accounting policies for derivative financial instruments is included in Note 3. “Fair Value Measurement of Financial Assets and Liabilities,” to our unaudited condensed consolidated financial statements included in Part I. Item 1. of this Form 10-Q.

A substantial portion of our debt bears interest at variable rates. If market interest rates increase, the interest rate on our variable rate debt will increase and will create higher debt service requirements, which would adversely affect our cash flow and could adversely impact our results of operations. We also have a revolving line of credit at variable interest rates. The general levels of LIBOR affect interest expense. We periodically use interest rate swaps to manage such risk. The net amounts to be paid or received under interest rate swap agreements are accrued as interest rates change, and are recognized over the life of the swap agreements as an adjustment to interest expense from the underlying debt to which the swap is designated. The related amounts payable to, or receivable from, the contract counterparties are included in accrued liabilities or accounts receivable in the unaudited condensed consolidated balance sheets.

As of March 28, 2020, all of our $686.6 million in credit facility debt was subject to variable interest rates, with a weighted average borrowing rate of 3.8%. After inclusion of the notional amount of $395.0 million of interest rate swaps fixing a portion of the variable rate debt, $291.6 million, or 42.5% of our debt, is subject to variable interest rates. Assuming an increase to market rates of 1.0% as of March 28, 2020, we would incur an annual increase to interest expense of approximately $2.9 million related to debt subject to variable rates.

Controls and procedures

As filed, 1,881 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures (as that term is defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) that are designed to ensure that information required to be disclosed in our reports under the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer (“CEO”) and our Chief Financial Officer (“CFO”), as appropriate, to allow timely decisions regarding required disclosures. Any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives.

In accordance with Rule 13a-15(b) of the Exchange Act, the Company carried out an evaluation, under the supervision and with the participation of its management, including its CEO and CFO, of the effectiveness of the design and operation of the Company's disclosure controls and procedures as of March 28, 2020. Based on that evaluation, the CEO and the CFO have concluded that the Company's current disclosure controls and procedures are effective in ensuring that material information relating to the Company required to be disclosed in the Company's periodic filings with the U.S. Securities and Exchange Commission ("SEC") is made known to them in a timely manner.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) that occurred during the first quarter of fiscal year 2020 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Risk factors

As filed, 15,568 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

For information regarding factors that could affect the Company's results of operations, financial condition and liquidity, see the risk factors discussed in Part I. Item 1A. “Risk Factors” in our 2019 Annual Report on Form 10-K and the additional risk factor supplemented in our Current Report on Form 8-K filed on March 19, 2020 (the “Current Report”), except as described below, there have been no material changes to the risk factors described in our 2019 Annual Report on Form 10-K and Current Report.

The scale and scope of the recent COVID-19 outbreak and resulting pandemic is unknown, has had a material adverse impact on our business and is expected to continue to adversely impact our business at least for the near term.

In December 2019, the COVID-19 disease was reported and in January 2020, the World Health Organization (“WHO”) declared COVID-19 a Public Health Emergency of International Concern. On February 28, 2020, the WHO raised its assessment of the COVID-19 threat from high to very high at a global level due to the continued increase in the number of cases and affected countries, and on March 11, 2020, the WHO characterized COVID-19 as a pandemic. The COVID-19 pandemic has adversely affected global economies, financial markets and the overall environment for our business, and the extent to which it may impact our future results of operations and overall financial performance remains uncertain.

The Company is following the recommendations of U.S. government and health authorities to minimize exposure risk for its associates, doctors, customers and patients. As a result, the Company announced on March 18, 2020, a temporary closure of its retail stores to the public. On April 27, 2020, the Company began the gradual re-opening of retail locations to the public with enhanced safety protocols and a focus on meeting the urgent and emergency eye health needs of patients and customers. The Company is closely monitoring this global health crisis and will reassess its strategy and operational structure on a regular, ongoing basis as the situation evolves.

The scale and scope of the COVID-19 pandemic has heightened and may continue to heighten the potential adverse effects on our business, operating results, cash flows and/or financial condition described in certain risk factors contained in our Annual Report on Form 10-K, including the impact of:

  • a disruption to our growth strategy of opening new stores and expanding our operations, including as a result of pausing new store openings;
  • our failure to recruit and retain vision care professionals for our stores;
  • a failure to adhere to existing laws and regulations or newly enacted state, local and federal vision care or healthcare laws and regulations in response to COVID-19;
  • an inability to maintain sufficient levels of cash flow from our operations to fund our business and growth strategy and the diminished availability of credit, higher cost of borrowing and lack of confidence in equity markets could make it more difficult for us to obtain additional financing on terms that are favorable to us;
  • a disruption to our distribution centers or optical laboratories, including those of our suppliers, could result in delays in the receipt of inventory and the delivery of merchandise, higher costs, longer lead times and impact the ability to fulfill customer orders;
  • travel restrictions and the shutdown of certain businesses on our suppliers and their sourcing operations and pricing practices;
  • the reduction in our marketing, advertising and promotional efforts as part of cost management could cause us to have difficulty in retaining existing customers and attracting new customers;
  • any significant failure, inadequacy, interruption or security breach on our information technology systems, as well as those of our vendors;
  • the impact of our substantial lease obligations, including negotiations with landlords during our temporary store closings, and our high occupancy costs reducing cash available for other purposes and limiting our flexibility;
  • any significant reductions or volatility in consumer demand for one or more of our products, which may be caused by, among other things, the temporary inability of consumers to purchase our products due to illness, quarantine or other travel restrictions, financial hardship, or a shift in customer behavior toward purchasing the products we offer from competitors who may have not closed their stores to the public or who may focus entirely on selling their products online;
  • the impact on our peak shopping quarters in the first half of the year and resulting impact on our annual operating results;
  • the distinct risks our e-commerce business faces, including changes in consumer behavior during the COVID-19 pandemic; and
  • significant operating and financial restrictions, including financial maintenance and restrictive covenants, in our recently amended credit agreement, that may limit the ability of us and our subsidiaries, under certain circumstances, to, among other things, incur additional indebtedness; engage in certain fundamental changes, including mergers or consolidations; make acquisitions, investments, loans or advances; pay or modify the terms of certain indebtedness; limitations in how we conduct our business; and our ability to raise additional debt or equity financing.

In addition, the COVID-19 pandemic may adversely impact our business and financial condition in other areas, including:

Operational Impacts

  • new or escalated government or regulatory responses in markets where we manufacture, sell or distribute our products, or in the markets of third parties on which we rely, could prevent or disrupt our business operations;
  • a future shutdown of one or more retail operations, distribution or laboratory facilities as a result of illness, government restrictions or other workforce disruptions;
  • higher costs in certain areas such as distribution, employee compensation, as well as incremental costs associated with newly added health screenings, temperature check, and enhanced cleaning and sanitation protocols to protect our associates, optometrists and customers; and
  • our operations could be disrupted if key members of our senior management or a significant percentage of our workforce or the workforce of our outsourced laboratories or suppliers are unable to continue to work because of illness, government directives or otherwise. In addition, the interruption of our or their system capabilities could result in a deterioration of our ability to fulfill and sell our products and services, provide customer service or perform other necessary business functions. Having shifted to remote working arrangements, we also face a heightened risk of cybersecurity attacks or data security incidents and are more dependent on internet and telecommunications access and capabilities that are less uniform than in our dedicated workspaces.

Financial Impacts

  • As described below, we anticipate that our financial results will continue to be materially impacted for the duration of the COVID-19 pandemic. While we believe that the long-term fundamentals of our business are largely unchanged, and anticipate that our operating results in future fiscal years will begin to reflect a more normal operating environment, the current economic and public health climate has created a high degree of uncertainty.
  • Revenues. We expect that the impact of COVID-19 on general economic activity will negatively impact our Owned & Host and Legacy segment total revenues. We began to experience this impact in March 2020 and expect it to persist and be more significant in the second quarter of 2020. We also expect this impact will further persist for the remainder of 2020 and possibly beyond, but the degree of the impact will depend on the extent and duration of the pandemic and the resulting economic contraction. As a result of the anticipated impact of the pandemic on our total revenues, we expect a decrease in our comparable store sales and adjusted comparable store sales figures during the remainder of fiscal year 2020.
  • Costs applicable to revenues. As a result of COVID-19, we expect to experience a change in our product sales mix with an increase in the share of contact lens sales compared to eyeglasses as contact lenses tend to be easier for a customer to select and order online compared to eyeglasses. Higher contact lens sales mix results in an increase in overall cost of products as a percentage of revenues as contact lenses have higher cost of sales as a percentage of revenues compared to eyeglasses. Due to reductions in revenues expected in the current year, we also expect to recognize lower vendor rebates which will unfavorably impact cost of products as a percentage of net product sales. Additionally, as a result of the lower production levels seen at our central laboratories and distribution centers, we expect our costs of sales as a percentage of revenues to increase from higher allocation of fixed costs. We also expect our cost of sales as a percentage of revenues to increase compared to prior years as a result of lower eye exam revenues and lower Legacy management fees earned while incurring costs for ophthalmologists, optometrists and optical technicians at a rate typically associated with a normal level of operations.
  • Selling, general and administrative. We have incurred and will continue to incur, general and administrative expenses primarily related to occupancy costs of our stores, advertising expenses, payroll related to store associates and unallocated corporate overhead expenses such as payroll, consulting and professional fees. We may experience elevated frequency and severity in our workers’ compensation claims liabilities by workers who demonstrate that the injury or illness arose both out of and in the course of their employment. We expect selling, general and administrative expenses as a percentage of revenues to increase compared to previous periods primarily due to expected overall decrease in revenues.
  • Asset impairment. The disruption in the economy experienced at the end of first quarter of 2020 and expected to persist through the end of the current fiscal year was considered by the Company in recording asset impairments during the first quarter. We evaluate impairment of long-lived tangible and ROU store assets at the store level and consider multiple factors including financial performance of the stores, regional and local business climates, future plans for the store operations and other qualitative factors. Asset fair values used in impairment are determined using an income approach based on discounted cash flows, which requires estimates and assumptions related to forecasted store revenue growth rates and store profitability. A significant decrease in the estimated cash inflows from our stores in future periods could affect the recoverability of our store level assets as well as other intangible assets of the Company such as goodwill, trademarks and contract relationship. Lower cash flows compared to estimates would lead to a material increase in the asset impairment expense recorded by the Company.

During the three months ended March 28, 2020, the Company evaluated whether a triggering event related to goodwill impairment had occurred because of the broad impacts of the COVID-19 pandemic. The Company expects the COVID-19 pandemic will continue to negatively affect its results of operations for the duration of its 2020 fiscal year. The Company has concluded a triggering event did not occur during the three months ended March 28, 2020, and, as a result, no interim impairment testing was required. However, as previously noted, the COVID-19 pandemic has had a material adverse effect on the Company’s business, and future conditions are highly uncertain. Future unfavorable developments may cause the Company to recognize an impairment of its goodwill. The Company will continue to evaluate the effects of the COVID-19 pandemic on its business.

  • Interest expense. On March 17, 2020, as a precautionary measure to preserve financial flexibility during the COVID-19 pandemic, we borrowed the remaining $146.3 million in available funds under our revolving credit facility. The total borrowings of $300.0 million represents the maximum borrowings permitted thereunder, at an interest rate of LIBOR plus a 1.50% per annum. On May 5, 2020, we entered into an amendment to our credit facility in order to suspend certain financial maintenance covenants contained therein for a specified period. In connection with the amendment, margins upon which interest is calculated on amounts outstanding under the facility were increased and the Company agreed to limit its ability to engage in certain transactions during the covenant suspension period, including the ability to declare or pay dividends, incur additional debt and make investments and dispositions. Refer to Management’s Discussion and Analysis of Financial Condition and Results of Operations, “Liquidity and Capital Resources” section above for more information. Lastly, we are continuing to evaluate additional operational and financial measures that we may elect to take as we continue to respond to the impact of COVID-19 on our business, including obtaining additional debt and/or equity capital to provide further liquidity in the coming months. There can be no assurance whether or when any such measures will be adopted. All of the above noted measures are expected to materially impact the Company’s interest expense in 2020 and later.
  • Inflation. It is possible that changes in economic conditions and steps taken by the federal government and the Federal Reserve in response to COVID-19 could lead to higher inflation than we had anticipated, which could in turn lead to an increase in our loss costs and the need to strengthen claims and claim adjustment expense reserves. To date, changes in material prices and general inflation have not materially impacted our business.

On March 27, 2020, the CARES Act was enacted in response to the COVID-19 pandemic. The CARES Act, among other things, accelerates a company’s ability to recover AMT refundable credits that otherwise could have been claimed in 2020 and 2021, to 2018 and 2019, with an option to elect recovery of the full credit amount for 2018. The CARES Act also includes a technical correction wherein qualified improvement property placed in service in 2018 and after is eligible for 100% bonus depreciation. We are evaluating the applicability of the CARES Act to the Company, and the potential impacts on our business. There is no guarantee that we will meet the eligibility requirements to participate in such programs or, even if we are able to participate, that such programs will provide meaningful benefit to our business. Consequently, it is not possible to estimate at this time the availability, extent or impact of any such relief.

The duration and extent of the impact from the COVID-19 pandemic depends on future developments that cannot be accurately predicted at this time, such as the severity and transmission rate of the virus, the extent and effectiveness of containment actions and the impact of these and other factors on our associates, customers, suppliers and partners. A more prolonged crisis will place greater strains on our liquidity. Such impact on our business, operating results, cash flows and/or financial condition may continue to be material.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2020-03-28. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2019-12-29 to 2020-03-28$469.7mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Selling, general and administrative3 months2019-12-29 to 2020-03-28$193.7mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2019-12-29 to 2020-03-28$16.9mus-gaap:OperatingIncomeLoss
Income tax3 months2019-12-29 to 2020-03-28−$282.0kus-gaap:IncomeTaxExpenseBenefit
Net income3 months2019-12-29 to 2020-03-28$9.7mus-gaap:NetIncomeLoss
Diluted EPS3 months2019-12-29 to 2020-03-28$0.12us-gaap:EarningsPerShareDiluted
Basic EPS3 months2019-12-29 to 2020-03-28$0.12us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2019-12-29 to 2020-03-2882,242,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow3 months2019-12-29 to 2020-03-28$86.1mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure3 months2019-12-29 to 2020-03-28$13.1mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Share repurchases3 months2019-12-29 to 2020-03-28$74.0kus-gaap:PaymentsForRepurchaseOfCommonStock
Cash and equivalentsAt period end2020-03-28$263.2mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2020-03-28$441.2mus-gaap:AssetsCurrent
Total assetsAt period end2020-03-28$2.22bnus-gaap:Assets
Current liabilitiesAt period end2020-03-28$287.5mus-gaap:LiabilitiesCurrent
Shareholders' equityAt period end2020-03-28$786.2mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001710155-20-000032. Last ingested by Listed: Nov 12, 2026, 17:21 ET. Listed shows no prices and gives no investment advice.